Saturday, 7 December 2019

Gonorrhea what all gynecologists should remember ?



All about  GONORRHEA
 Gonorrhea remains the second  most commonly reported modifiable  disease in the United States. The incidence of gonorrhea in  the United States for 2012  was 107.5 cases per 100,000 persons  which is  an increase  of 4  percent  since 2011   . the  highest rates in  women of   any ethnicity were in the  groups aged 20  to24 years  and   15 to 19 years . Its prevalence in prenatal   prevalence of  5 to 10 percent  . Risk  factors include single marital   status adolescence  poverty drug abuse prostitution other STIs and lack of prenatal  care. Gonococcal  infection in up to 40   percent of  infected women   . In most pregnant women gonococcal  infection is limited to the lower   genital tract- the cervix urethra and periurethral and vestibular glands. Acute salplingitis  is rare  in pregnancy   but pregnant  women  account for a disproportionate  number of disseminated  gonococcal   infections .
Gonococcal infection may have  deleterious effects in any trimester. There is an association between  untreated gonococcal  Cervicitis   and septic abortion as well as infection  after voluntary abortion. Preterm  delivery   prematurely ruptured  membranes   chorioamnionitis and postpartum infection  are reported to be more  common in women   infected with  Neisseria gonorrhoeae. Bleich and coworkers reviewed outcomes  of 32  pregnant  women admitted  to parkland  Hospital for disseminated gonococcal infection. Although  all the women   promptly responded to appropriate  antimicrobial therapy  one stillbirth was attributed to gonococci sepsis.
Screening and treatment
The U.S  Preventative Services  Task Force  recommends gonorrhea screening  for all sexually  active women , including  pregnant women if they are  at increased risk  . Risk  factors  include age < 25  years prior   gonococcal infection, other  STIs prostitution new    or multiple sexual   partners drug use and inconsistent conform  use . for  women who  test positive  screening for syphilis chamydia trachomatis and HIV  should   precede treatment, if possible. If  chlamydial testing  is unavailable  presumptive  therapy is given. Screening for  gonorrhea in women is by   culture or   nucleic  acid amplification  tests Rapid tests  for gonorrhea although available do not yet reach  the sensitivity or specificity of culture  or NAAT  .
Gonorrhea treatment has evolved during   the past decade  due to the  ability of N gonorrhoeae to rapidly  develop  antimicrobial resistance  . Rapid  development of fluoroquinolone resistance caused  the CDC  to remove  that therapeutic   class  from its treatment  guidelines in 2007. The Gonococcal Isolate Surveillance  to monitor  trends in  gonococcal  antimicrobial   agents currently recommended for gonorrhea  treatment  . this global  public  health  threat  has led the CDC  in 2012  to change  the gonorrhea treatment  recommendations.
The  updates recommendations for treatment  of uncomplicated   gonococcal  infection during  pregnancy. The   increased Ceftriaxone  dose of 250 mg should be given  along with 1 gram of azithromycin. The latter  provides another  drug with a different mechanism of action against N gonorrhoeae and treats chlamydial co infections. Cefixime tablets  should  be  reserved   for situations that preclude Ceftriaxone  treatment. If they  are used a test of cure should be  performed  1 week  after  treatment. Azithromycin  2 grams  orally  as a single  dose can be used   in cephalosporin allergic women. However   this treatment  should be limited   due to emerging macrolide resistance  . Treatment is also recommended  for sexual contacts. A test of cure  is   unnecessary if   symptoms  resolve  but because  gonococcal reinfection  is common a second screening   in late pregnancy should be  considered for women  treated  earlier.
Disseminated  Gonococcal Infections
Gonococcal  bacteremia may cause  disseminated infections  that manifest  as petechial  or pustular skin lesions arthralgias  septic   arthritis or tenosynovitis. For treatment  the Centers for Disease Control  and Prevention has recommended Ceftriaxone 1000 mg intramuscularly  or intravenously every 24 hours  . treatment  should be continued  for 24 to 48  hours after improvement and  therapy  is then  changed  to an oral gent to complete  1 week of therapy , Prompt recognition   and antimicrobial treatment   will usually result  in favorable outcomes in pregnancy   . Meningitis and endocarditis   rarely  complicate pregnancy but they may be   fetal  . For gonococcal  endocarditis  Ceftriaxone 1000  to 2000  mg IV  every 12 hours   should be  continued for at least 4 weeks   and for meningitis , 10 to 14 days


No comments:

Post a Comment